Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data

Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data

Background and Purpose: Evidence for induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) in nasopharyngeal carcinoma (NPC) was derived from landmark clinical trials excluding the T3N0, T3N1, T4N0 subgroups. This study used Epstein-Barr virus (EBV) DNA to select IC beneficiaries from t...

Full description

Bibliographic Details
Main Authors: Cheng Xu, Shu Zhang, Wen-Fei Li, Lei Chen, Yan-Ping Mao, Ying Guo, Qing Liu, Jun Ma, Ling-Long Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Oncology
Subjects:
nasopharyngeal carcinoma
Epstein-Barr virus
induction chemotherapy
concurrent chemoradiotherapy
recursive partitioning analysis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01343/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01343/full

Similar Items